Suzhou Ribo Life Science Adopts ArisGlobal's LifeSphere® MultiVigilance to Enhance Clinical Trial Data Management

MIAMI, Nov. 1, 2021 /PRNewswire/ -- A leading provider of life sciences software that automates core drug R&D through its end-to-end drug development technology platform LifeSphere®ArisGlobalToday, it was announced that a formal partnership has been established with Ribo Life Science, an innovative R&D company dedicated to developing nucleic acid therapeutics and related products utilizing RNA interference (RNAi) technology. Ribo Life Science will leverage the Chinese and English versions of ArisGlobal’s LifeSphere Multivigilance to manage its drug safety data and meet regulatory requirements for advancing its products to the clinical trial phase.

“Clinical drug trials generate a substantial volume of safety data, and careful, purposeful insights are essential to safely bringing drugs to market. Ribo Life Science maintains numerous independently developed and partnered oligonucleotide therapeutic pipelines. LifeSphere Multivigilance can provide data models that connect isolated safety datasets across the global market, integrating them into a valuable data architecture,” said Beena Wood, Vice President of Safety at ArisGlobal.

Multivigilance is a solution within the LifeSphere safety product line. It is an end-to-end automated system designed to help pharmacovigilance teams save time and effort, ensure future-proof compliance, and align global teams. The platform leverages artificial intelligence to streamline existing pharmacovigilance workflows and ensures 100% compliance with current and future regulatory requirements.

"As Ribo Life Science continues to advance its innovative drugs into clinical trials on a global scale, we need to select a pharmacovigilance system that delivers stable performance, robust data management capabilities, and an innovative spirit. We have full confidence in ArisGlobal’s products, and we believe that as Ribo Life Science continues to grow, our partnership will deepen further," said Ms. Fu Jing, Vice President of Ribo Life Science.

Previously, at its flagship conference Breakthrough 2021, ArisGlobal held key discussions on safety, automation, artificial intelligence applications, and data, and released the 2021 State of the Industry Report on Life Sciences R&D Technologies.

For more information about ArisGlobal, please visit:www.arisglobal.com。